PT - JOURNAL ARTICLE AU - Lambert, David S. AU - Picó, Ana María AU - Vincent, Justin D. AU - Deych, Elena AU - Coglianese, Erin AU - Schilling, Joel D. AU - Vader, Justin M. AU - Yang, Bin Q. TI - MELD-XI Predicts Severe Right Ventricular Failure after HeartMate 3 Implantation in a Contemporary Cohort AID - 10.1101/2024.07.09.24310179 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.09.24310179 4099 - http://medrxiv.org/content/early/2024/07/10/2024.07.09.24310179.short 4100 - http://medrxiv.org/content/early/2024/07/10/2024.07.09.24310179.full AB - Background Right ventricular failure (RVF) after left ventricular assist devices (LVAD) is associated with significant morbidity and mortality and identifying patients at risk for severe RVF is an important clinical goal. Current risk prediction models were not developed in contemporary LVAD populations and have limited clinical applicability.Objectives To evaluate whether the Model for End Stage Liver Disease – eXcluding INR (MELD-XI) can predict severe RVF after HeartMate 3 (HM3) implantation.Methods We retrospectively analyzed all adult patients who received HM3 LVAD as initial implantation at two academic medical centers. We assessed whether MELD-XI is an independent risk factor for severe RVF in multivariate analysis and compared the predictive accuracy of MELD-XI with previously published risk scores. We also investigated the relationship between MELD-XI and markers of right ventricular function and whether MELD-XI was associated with death or pump exchange at 1-year follow-up.Results Our study included a total of 246 patients, of which 74 (30%) experienced severe RVF. After adjusting for relevant covariables, MELD-XI was independently associated with severe RVF (OR 1.18, CI 1.09-1.29, p<0.001) and performed similarly to the EUROMACS and Michigan RVF risk scores. In addition, MELD-XI was not reflective of traditional echocardiographic or hemodynamic measures of right ventricular function. Finally, MELD-XI ≥ 14 predicted worse in-hospital mortality.Conclusions Among patients undergoing HM3 implantation, MELD-XI is independently associated with an increased risk of RVF and in-hospital mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by the Washington University School of Medicine in St. Louis Mentors in Medicine program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the IRB at both Washington University School of Medicine in St. Louis and Massachusetts General Hospital.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data will be available upon request of corresponding author.